Editas Medicine (EDIT) Operating Leases (2019 - 2025)

Editas Medicine (EDIT) has 7 years of Operating Leases data on file, last reported at $12.1 million in Q4 2025.

• On a quarterly basis, Operating Leases fell 40.77% year-over-year to $12.1 million in Q4 2025; TTM through Dec 2025 was $12.1 million, a 40.77% decrease from a year earlier, with the FY2025 full-year figure at $12.1 million, down 40.77% from the prior year.
• Operating Leases for Q4 2025 stood at $12.1 million, down from $13.6 million in the prior quarter.
• Over the last five years, Operating Leases for EDIT reached as high as $32.9 million in Q4 2022 and fell as low as $9.3 million in Q3 2022.
• Historically, Operating Leases has averaged $19.5 million across 5 years, with a median of $20.4 million in 2024.
• Across the five-year window, Operating Leases sank 52.5% in 2022 and soared 167.13% in 2023, its largest moves.
• Year by year, Operating Leases stood at $16.1 million in 2021, then soared by 104.52% to $32.9 million in 2022, then decreased by 25.84% to $24.4 million in 2023, then fell by 16.38% to $20.4 million in 2024, then tumbled by 40.77% to $12.1 million in 2025.
• Per Business Quant data, the three most recent Operating Leases figures were $12.1 million in Q4 2025, $13.6 million in Q3 2025, and $15.0 million in Q2 2025.